
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc. has raised the probability of approval for its RP1 + Opdivo combination therapy in anti-PD-1 failed melanoma patients to 85%, indicating significant positive momentum based on recent clinical trial results. The company has secured an improved financial runway into early 2027, bolstered by a strategic amendment to its Hercules Capital loan, which includes $35M in immediate funding and the potential for an additional $120M upon achieving post-approval milestones. Additionally, the RP1 + Opdivo therapy has demonstrated robust efficacy, with an overall response rate increase from 11.5% to 29.8% when compared to prior anti-PD-1 treatments, alongside a favorable safety profile characterized by low rates of severe treatment-related adverse events.
Bears say
Replimune Group Inc. presents a concerning financial outlook, reporting a significant net loss of $70.9 million for FY3Q26, which, while slightly better than estimates, underscores ongoing financial challenges. Key risks impacting the company's future prospects include the potential inability to demonstrate compelling efficacy and safety data in clinical trials, regulatory approval hurdles for the RP1 product, and the possibility of medium- to long-term shareholder dilution. Despite some optimism regarding the FDA's acceptance of a resubmission for RP1, the overarching risks and negative financial metrics raise caution among potential investors.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares